Abstract. This prospective study aimed to explore the diagnostic value of superb microvascular imaging (SMI) in differentiating Breast Imaging Reporting and Data System (BI-RADS) 4 breast lesions compared with conventional ultrasonography (US). A total of 111 patients with 116 breast lesions underwent grayscale ultrasound (US), colour Doppler flow imaging (CDFI) and SMI breast imaging between February 2016 and May 2018. CDFI and SMI were performed to evaluate vascular quantity, morphology, and distribution characteristics. The detection of malignancy was compared between grayscale US alone, US + CDFI and US + SMI in terms of the BI-RADS stratification system. SMI was observed to be significantly more accurate in distinguishing malignant breast lesions (86.67%) compared with CDFI (80.00%) (P<0.001). Among malignant lesions, SMI detected 80.00% of those that contained ≥4 vessels, while CDFI only detected 56.67%. Penetrating and branching vessels were identified by SMI in 53.33% of malignant breast lesions and by CDFI in 10.00%. There was no significant difference in vascular distribution by SMI (P=0.094) and by CDFI (P=0.087). US + SMI was associated with higher sensitivity, specificity, and accuracy rates (86.67, 83.72 and 84.48%, respectively) compared with US + CDFI (80.00, 72.09 and 74.14%, respectively). The area under the curve values from receiver operating characteristic analysis of US + SMI, US + CDFI and US alone were 0.852 [95% confidence interval (CI): 0.768-0.936)] 0.760 (95% CI: 0.660-0.860), 0.698 (95% CI: 0.589-0.807), respectively (P<0.001). SMI yielded more detailed vascular information associated with malignant breast masses when compared with conventional US. Therefore, as an adjunct to grayscale, SMI exhibited a markedly improved diagnostic capability in distinguishing malignant and benign breast lesions, particularly those of BI-RADS category 4.
Introduction
Breast cancer has been among the leading causes of cancer-associated mortality among Chinese women in the past ten years (1) . The 5-year survival rates vary from 100% (Stage I) to 22% (Stage IV) (2); thus, early diagnosis is crucial. Tumor growth has been demonstrated to be largely dependent on angiogenesis (3) . The formation of new blood vessels serves a pivotal role in the local growth, invasion and distant metastasis of breast cancer (4) . Therefore, this identifying this distinct characteristic between malignant and benign breast lesions may represent a supplementary method for improving diagnostic performance and accuracy. Color Doppler flow imaging (CDFI) and power Doppler flow imaging have been extensively applied in clinical practice (5, 6) . However, such non-invasive methods adjunct to grayscale ultrasonography (US) exhibit low sensitivity in detecting microvascularity (7) , and are largely dependent on the mean Doppler frequency shift, with inevitable loss of low-velocity blood flow information. By contrast, superb microvascular imaging (SMI), an emerging Doppler US method, suppresses clutter to delineate a wider range of blood flow signals with a higher resolution. Therefore, SMI is capable of detecting low-velocity and high-velocity flow, while CDFI is unable to detect very low-flow states due to the different blood flow extraction principles (8) . Previous trials have confirmed the higher sensitivity of SMI in depicting central and peripheral vessels in hepatic lesions, compared with CDFI (9, 10) .
The American College of Radiology first introduced the Breast Imaging Reporting and Data System (BI-RADS) in 2003, which was updated in 2013 (11) . This reporting system includes a wide range of US findings for malignancy classifications, such as shape and echogenicity pattern and posterior acoustic characteristics. The updated version added subdivisions to category 4, taking into consideration the fact that BI-RADS category 4 is the most controversial (12) . The likelihood of malignancy in that stratification ranges from 2-95% (13), as BI-RADS category 4 breast masses are affected by a diverse range of clinical factors such as abscess, hematoma and fat necrosis (14) .
To the best of our knowledge, few studies have applied the SMI technique to differentiate the malignancy among BI-RADS 4 breast lesions. Therefore, the aim of the present study was to explore the diagnostic value of SMI in differentiating between malignant and benign BI-RADS 4 breast lesions compared with conventional US.
Patients and methods
Clinical data. Between February 2016 and May 2018, 291 patients were diagnosed with breast lesions detected by conventional US in our hospital. In total, 116 lesions in 111 patients (age range, 16-64 years; mean age, 47.13±9.29 years) were recruited in this prospective study. Among the 111 patients, 5 presented with 2 lesions. The flowchart of the selection process is presented in Fig. 1 and the inclusion criteria were as follows: i) Breast lesion detectable by US; ii) breast lesion was classified as BI-RADS 4 category; and iii) no history of treatment prior to US examination. The exclusion criteria were as follows: i) Incomplete data (n=49); and ii) breast surgery or chemotherapy for the same lesions (n=9). The mean diameter of the lesions was 17.93±8.51 mm (range, 8.0-48.3 mm), while the mean depth was 26.45±11.35 mm (range, 8.1-47.3 mm). All lesions were pathologically confirmed by a US-guided core needle biopsy and/or surgery according to standard clinical protocols. This prospective study was approved by the Ethics Committee of Shanghai Pudong New Area People's Hospital (Shanghai, China). All patients in the present study were provided with information on all the examinations and procedures and provided written informed consent to participate in the study.
Equipment and methods.
All patients initially underwent a grayscale US examination, using a TOSHIBA Aplio 500 (Toshiba Medical System Corporation, Tokyo, Japan) with high-frequency (14 MHz) line array transducers. When a breast lesion was detected, the lesion size, depth, shape and other US characteristics, including the margin, echogenicity and posterior acoustic elements were recorded. Grayscale US was followed by CDFI (frame rate 10-15 Hz) and SMI (frame rate >50 Hz) to evaluate vascular quantity, morphology and distribution. The velocity scope of SMI was adapted to <2.5 cm per second. Gentle pressure was applied through the transducer to prevent vessel collapsing. During the examination, patients were placed in the supine position with the arms elevated and were instructed to breathe calmly.
The same radiologist (YCZ) with >3 years of experience in breast US and 1-year experience in SMI conducted all examinations. The same imaging area for CDFI and SMI vascular blood flow images were acquired as the reference area for the breast tissue (Figs. 2 and 3 ). All images were recorded and transferred to the hospital's internal online database. The images were evaluated by two radiologists (YZ and SHD), who had 10-and 5-years respective experience in CDFI and breast imaging, and 2 years in SMI. A two-stage rating process was applied to the imaging of the breast lesions. Each breast lesion was first rated according to BI-RADS based on the aforementioned US characteristics; thereafter, vascular quantity, morphology and distribution were rated based on CDFI and SMI findings. Vascular quantity was graded according to the Adler's classification (15) as follows: i) Absent, grade 0; ii) minimal, grade 1; iii) moderate, grade 2; or iv) marked, grade 3, dependent on the amount of blood flow in the region of interest (15) . Grade 0 referred to no blood flow detected; minimal (grade 1) flow generally referred to 1 or 2 pixels containing flow (<0.1 cm in diameter); moderate (grade 2) referred to a certain number of small vessels and/or a main vessel and marked (grade 3) vascularity was defined as ≥4 vessels visualized (15) . Morphological characteristics were evaluated using a classification that included 7 categories, including not applicable (N/A), linear, dot-like, penetrating, branching, penetrating and branching, and shunt. Vessel distribution was further divided into three categories, peripheral, central, and both peripheral and central, respectively. Based on these findings, the two aforementioned radiologists then re-corrected BI-RADS stratification. If any disagreement occurred, a third senior radiologist (QJ), with an experience of >15 years in breast US and 2 years in SMI, was consulted. All radiologists were blinded to the pathological findings.
Statistical analysis. The χ 2 test or Fisher's exact tests were applied for categorical variables, while an independent-samples t-test was applied for the comparison of continuous variables. Quantitative data are expressed as mean ± standard deviation when normally distributed. The findings on new vessel formation from CDFI and SMI were compared between the malignant and benign lesions using χ 2 test. A receiver operating characteristics (ROC) curve was formulated to determine the diagnostic value of CDFI and SMI. The areas under the curves (AUCs) of different diagnostic modalities were compared using the χ 2 test. Statistical analysis was performed using the pathological results as the diagnostic gold standard. P<0.05 was considered to indicate statistically significant differences. Data analysis was performed using SPSS 25.0 software (IBM Corp., Armonk, NY, USA).
Results

US characteristics.
Of the 116 breast lesions examined, 30 (25.9%) lesions were pathologically confirmed as malignant. The malignant lesions were further categorized as invasive ductal carcinomas (n=17), ductal carcinoma in situ (n=6), tubular carcinomas (n=2), invasive lobular carcinomas (n=2) and mucinous carcinomas (n=3). Among the 86 benign lesions, the most common benign pathological result was fibrocystic change (n=24), followed by fibroadenoma (n=23) and ductal hyperplasia (n=18). The pathological results of the breast masses are summarized in Table I Evaluation of microvasculature parameters in breast lesions using CDFI and SMI. The vascular quantity was evaluated using Adler's classification, as shown in Table III . CDFI and SMI exhibited a noticeable variance between malignant and benign masses (P<0.001). CDFI identified 21 breast masses as avascular, while SMI revealed absent vascularity in 17 of those masses, which indicated that SMI was more efficient in distinguishing microvessels. Based on the identification of the microvasculature, SMI detected 80.00% of malignant lesions that contained ≥4 vessels, while CDFI only identified 56.67% of malignant breast lesions with rich blood flow signals. In comparison, the majority of benign lesions were avascular (CDFI: 22.1%; SMI: 18.6%) or hypo-vascular (CDFI: 53.5%; SMI: 52.3%; Table III ). Avascular lesions were rarely identified in malignant breast lesions; under CDFI examination, 2 out of 30 malignant lesions exhibited this feature, whereas SMI detected one malignant lesion with no vascularity. In addition, the morphology of the vessels differed significantly different between CDFI and SMI (P<0.01). Penetrating and branching vessels were detected in malignant breast lesions using CDFI and SMI (53.33 and 10.00%, respectively). However, SMI exhibited higher sensitivity in detecting complex morphological characteristics in benign breast masses, while CDFI was unable to display penetrating, branching and shunt vessels in benign breast masses. In terms of vessel distribution, malignant breast lesions more frequently exhibited peripheral and both peripheral and central distribution compared with central distribution alone, whereas benign masses more frequently exhibited central and both peripheral and central distribution. However, there was no significant difference between benign and malignant breast lesions in terms of vessel distribution using either CDFI (P=0.269) or SMI (P=0.220) ( Table III) .
Risk of malignancy grading and diagnostic performance of US, US + CDFI and US + SMI.
In terms of subdivision of the BI-RADS category 4 of breast lesions, none were downgraded by either CDFI or SMI. A total of 5 breast neoplasms were upgraded to category 5 with CDFI, while 12 breast neoplasms were upgraded to category 5 following SMI examination (Fig. 4) . Regarding the 86 benign lesions, 72, 62 and 57 were graded as BI-RADS 4a under US + SMI, US + CDFI, and US examination alone. None of the benign lesions were graded as BI-RADS 5 under any of the three examinations. When breast lesions rated as BI-RADS 4a were considered as benign, and the remaining breast lesions rated as BI-RADS 4b, 4c and 5 as malignant, the sensitivity, specificity and accuracy rate for SMI were 86.67, 83.72 and 84.48%, respectively; the sensitivity, specificity and accuracy rate for CDFI were 80.00, 72.09 and 74.14% (Table IV) (Fig. 5 ). There was a significant difference in the AUC value between US + CDFI and US + SMI (P<0.001).
Discussion
US has been widely applied as a first-line diagnostic technique in differentiating malignant and benign tumors based on the evaluation of angiogenesis and the growth of irregular vascular structures (16, 17) . Compared with magnetic resonance imaging and contrast-enhanced US, Doppler US has the advantages of being simpler, more cost-effective and more risk-free. CDFI, one of the most widely used US techniques, provides valuable data for evaluating blood flow, but with limitation in detecting vessels <0.1 mm, as CDFI is generally associated with data loss due to movement artifacts attributed to the single-dimension filter (18) . Due to the advances in US techniques, SMI is a pioneering technique that has the ability to visualize lower-speed bloodstream without motion artifacts (7). This advantage has been widely reported in the analysis of microvascular flow within thyroid nodules (19) , testicular (20) and hepatic tumors (21) . Multiple studies support the efficacy of SMI in specifically visualizing minute vessels and slow speed blood flow, with high resolution and fewer motion artifacts. After observing 123 breast masses, Ma et al (22) concluded that SMI (83.7%) achieved a better visualization of vascularity compared with CDFI (74.8%). The study of Zhu et al (23) evaluated microvascular blood flow in 123 breast lesions in 121 patients and demonstrated that the improved visualization of the microvasculature, including low-flow vessels, with SMI (87.80%) when compared with CDFI (78.05%). These studies support the findings of the present study, which demonstrated that SMI detected the presence of vessels in 99 breast masses (85.3%), while CDFI only detected blood flow in 95 masses (81.90%). Among avascular breast masses, only one was pathologically proven to be malignant. In the present study, malignant breast lesions tended to have ≥4 vessels based on the Adler's classification. Specifically, 80.00% of the malignant breast lesions were rated as grade 3 using SMI, whereas CDFI classified only 56.67% of such lesions as grade 3. Therefore, malignant breast neoplasms displayed more enriched flow signals. This finding was consistent with the nature of neoplastic angiogenesis, as malignant and benign lesions exhibit distinct degrees of neo-vasculature development (24) . Vascularity growth is a closely associated with neoplastic proliferation (25) .
In addition to vessel quantity, the present study also observed vascular morphology and distribution as potential indicators of malignancy. A high correlation between breast cancer angiogenesis, vascular morphology and distribution has been reported (26) . One of the critical characteristics of malignant lesions is the presence of penetrating and complex branching patterns (27) . Xiao et al (28) indicated that penetrating, spiculated or radially arranged vessels are more likely to be identified in malignant breast lesions. Zhan et al (29) , demonstrated that SMI depicted an increase in the median number of penetrating vessels when compared with CDFI. Similarly, in the present study, no shunt vessels were detected by CDFI, whereas 7 malignant breast lesions with shunt vessels were identified by SMI. With regards to the distribution of vascularity, there was no statistically significant difference between CDFI and SMI. Therefore, our findings re-confirmed that both the number and morphological characteristics of vessels are key to differentiating breast malignancies (30) .
The overgrowth of immature capillaries from the vessels surrounding the lesions may explain the findings of the present study.
In the present study, the risk of malignancy was based on the BI-RADS system. SMI was demonstrated to be superior in terms of sensitivity (86.67%, 26/30), specificity (83.72%, 72/86) and accuracy rate (84.48%, 98/116). However, the increased efficacy of SMI in extracting microvascular information may lead to an increase in false positive diagnoses. For example, 1 fibroadenoma and 1 papilloma were observed to be delineated with penetrating and branching vessels, respectively under SMI examination. When integrating with other vascular characteristics, the two benign breast lesions were upgraded from 4a to 4c and 4b, respectively. Furthermore, calcifications in the hyperechoic area may result in the misdiagnosis of true negative cases.
There were certain limitations to the present study. Firstly, the study was only conducted in one center with limited pathological groups. Second, all the examinations were conducted by one radiologist and, consequently, there was no interpretation of inter-observer differences. Third, the inclusion of samples may be biased, as BI-RADS category 3 breast masses were not included in the present study, although none of the examined breast masses were downgraded to category 3 neither by CDFI or SMI. Therefore, further research should include larger samples, from multiple centers and include the full scale of BI-RADS categories. In summary, the present study compared SMI with CDFI to evaluate vascular quantity, morphology and distribution for differentiating between malignant and benign BI-RADS 4 category breast lesions. SMI was able to overcome the shortcomings of CDFI in detecting low-velocity blood flow due to motion artifacts. Our findings demonstrated that SMI is superior to CDFI in identifying and characterizing vascular details further. We also reported that, as an adjunct to grayscale US, SMI exhibited notable diagnostic performance in distinguishing between malignant and benign BI-RADS category 4 breast lesions.
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